Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022
View
General Hepatology
5
Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022
View
General Hepatology
5
Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022
View
General Hepatology
5
Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022
View
General Hepatology
5
Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
